Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R9HI
|
||||
| Former ID |
DCL000391
|
||||
| Drug Name |
SB-742457
|
||||
| Synonyms |
GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease; Dementia [ICD9: 290-294, 331.0; ICD10:F01-F07, G30] | Phase 2 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H19N3O2S
|
||||
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4
|
||||
| InChI |
1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
|
||||
| InChIKey |
JJZFWROHYSMCMU-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16342129, 23432880, 42336247, 57304406, 80580213, 103756096, 104152994, 125646223, 126671677, 131320697, 135261679, 137099831, 141802492, 162009827, 162210546, 162223698, 162567130, 163620787, 163686112, 174529998, 174538911, 186014821, 187072839, 188932818, 196409663, 198952878, 218903267, 223675869, 223947486, 227869399, 242059992, 245722800, 251910589, 251963241, 251971156, 252450570
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 6 receptor | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020107) | ||||
| REF 2 | 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. | ||||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.